- iBio (NYSEMKT:IBIO) appointed Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer, effective Jan. 18, 2021.
- "Given his prior experience leading organizations with novel protein expression platforms to build proprietary product pipelines, Dr. Brenner should be uniquely suited to assist iBio with a similar transformation. Notably, he also brings a track-record of effective new target search and evaluation, as well as establishing productive collaborations," chairman & CEO Tom Isett commented.
- Most recently, Dr. Brenner served as the CSO at Recursion Pharmaceuticals.
- Shares +1.72% premarket